Overview

CYP2C19 Genotype Predictor of Gastric Acid Suppression

Status:
Withdrawn
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
If CYP2C19 genotype can predict the efficacy of healing erosive esophagitis and gastric acid secretion in patients taking once a day omeprazole.
Phase:
Early Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Omeprazole